Lipigon Pharmaceuticals AB (publ) reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported revenue was SEK 0.037 million compared to SEK 0.463 million a year ago. Net loss was SEK 9.2 million compared to SEK 14.42 million a year ago.

Basic loss per share from continuing operations was SEK 0.45 compared to SEK 1.48 a year ago. Diluted loss per share from continuing operations was SEK 0.45 compared to SEK 1.48 a year ago.